Ernexa Therapeutics (ERNAW) Non-Current Assets (2010 - 2026)

Ernexa Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $547000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 80.79% year-over-year to $547000.0; the trailing twelve-month figure through Mar 2026 stood at $8.8 million (down 82.9% YoY), and the FY2025 full-year result was $2.7 million, down 7.4% from the prior year.
• Non-Current Assets for Q1 2026 stood at $547000.0, down from $2.7 million in the prior quarter.
• The five-year high for Non-Current Assets was $45.2 million in Q3 2023, with the low at $547000.0 in Q1 2026.
• Historically, Non-Current Assets has averaged $15.8 million across 5 years, with a median of $5.1 million in 2022.
• Annual changes were most pronounced in 2023 — Non-Current Assets soared 791.15% — and 2025, when it plunged 93.49%.
• Ernexa Therapeutics' Non-Current Assets stood at $8.6 million in 2022, then surged by 359.79% to $39.5 million in 2023, then slumped by 92.62% to $2.9 million in 2024, then retreated by 7.4% to $2.7 million in 2025, then plunged by 79.75% to $547000.0 in 2026.
• The last three Non-Current Assets figures came in at $547000.0 (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.